CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

The Hallmarks of Cancer

2000 • 27,569 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Cell Signaling by Receptor Tyrosine Kinases

2010 • 7,477 citations

Untangling the ErbB signalling network

2001 • 6,623 citations

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1984 • 2,762 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

1984 • 2,564 citations

NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2000 • 2,394 citations

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

1985 • 1,523 citations

The EGF receptor family as targets for cancer therapy

2000 • 1,339 citations

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

1995 • 1,108 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor

1996 • 1,021 citations

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 • 1,013 citations

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

1994 • 932 citations

Specificity within the EGF family/ErbB receptor family signaling network

1998 • 804 citations

Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

1996 • 772 citations

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

1993 • 724 citations

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

1997 • 719 citations

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

1987 • 619 citations

The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*

1992 • 585 citations

Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors

1999 • 548 citations

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.

1995 • 546 citations

ERBB2 oncogene in human breast cancer and its clinical significance

1998 • 457 citations

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1999 • 445 citations

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1999 • 440 citations

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1999 • 440 citations

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1998 • 414 citations

A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.

1996 • 407 citations

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

1999 • 300 citations

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

1999 • 296 citations

Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

1999 • 293 citations

Receptor tyrosine kinases as targets for anticancer drugs

2002 • 251 citations

Expression of the ERBB3 gene product in breast cancer

1992 • 237 citations

Bivalence of EGF-like ligands drives the ErbB signaling network

1997 • 226 citations

Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents

1999 • 217 citations

EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival

2001 • 215 citations

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1994 • 212 citations

Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2

1996 • 208 citations

Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation

1999 • 192 citations

Roles of Erbb family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival

2002 • 191 citations

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents

2000 • 191 citations

The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis

1999 • 190 citations

Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types

1998 • 188 citations

The role of EGF-related peptides in tumor growth

2001 • 188 citations

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)

1997 • 186 citations

Targeting the epidermal growth factor receptor

2004 • 183 citations

Expression of c-erbB3 protein in primary breast carcinomas

1998 • 181 citations

Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.

2000 • 169 citations

Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes

1998 • 163 citations

The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients

1994 • 161 citations

Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

2000 • 159 citations

Characterization of neuronal dystrophy induced by fibrillar amyloid β: implications for Alzheimer’s disease

2002 • 149 citations

Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site

1997 • 149 citations

Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.

2000 • 147 citations

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1995 • 133 citations

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

1999 • 133 citations

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

1998 • 132 citations

Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes

1998 • 130 citations

Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy

1999 • 128 citations

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators

1996 • 128 citations

Tyrosine kinase signalling in breast cancer

2000 • 128 citations

Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

2001 • 123 citations

Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor

2000 • 121 citations

c-erbB-4 protein expression in human breast cancer

2000 • 107 citations

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit thein vitro growth of human head and neck cancer cells and cause rapid tumor regressionin vivo

2000 • 106 citations

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

2002 • 105 citations

The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing

1999 • 105 citations

The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer

1998 • 97 citations

c‐erbB‐2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells

1999 • 96 citations

Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.

1999 • 85 citations

Targeting the epidermal growth factor receptor: a clinical reality.

2001 • 84 citations

Biological Response to ErbB Ligands in Nontransformed Cell Lines Correlates with a Specific Pattern of Receptor Expression

1998 • 82 citations

Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia

1999 • 80 citations

The c-erbB3/HER3 receptor in human cancer.

1996 • 72 citations

Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.

2001 • 72 citations

Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.

2000 • 70 citations

The epidermal growth factor receptor in breast cancer.

1997 • 64 citations

Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.

1997 • 62 citations

EGF-related peptides and their receptors in mammary gland development.

1997 • 59 citations

Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

2001 • 55 citations

EGF-R expression in ductal breast cancer: proliferation and prognostic implications.

1997 • 47 citations

The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.

1997 • 45 citations

Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer1Published in conjunction with A Wisconsin Gathering Honoring Waclaw Szybalski on the occasion of his 75th year and 20 years of Editorship-in-Chief of Gene, 10–11 August, 1997, University of Wisconsin, Madison, WI, USA.1

1998 • 44 citations

The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms

2000 • 44 citations

Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue

1993 • 39 citations

Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.

1995 • 33 citations

Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates

2000 • 26 citations

What went wrong with Iressa?

2002 • 23 citations

ErbB-4: a receptor tyrosine kinase

2002 • 22 citations

ErbB receptor tyrosine kinase inhibitors as therapeutic agents

2002 • 20 citations

The ErbB 2 Oncogene and Chemotherapy: a Mini-Review

1997 • 19 citations

EGF Family Receptors and Their Ligands in Human Cancer

1998 • 19 citations

Deleted Work

1955 • 0 citations